

## عنوان مقاله:

Differences in growth promotion, drug response and intracellular protein trafficking of FLT<sup>3</sup> mutants

## محل انتشار:

مجله علوم پایه پزشکی ایران، دوره 17، شماره 11 (سال: 1393)

تعداد صفحات اصل مقاله: 7

## نویسندگان:

Baratali Mashkani - *Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran*  
Discipline of Medical Biochemistry, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia

Renate Griffith - *School of Medical Sciences/Pharmacology, University of New South Wales, Sydney, NSW 2052, Australia*  
School of Environmental and Life Sciences, University of Newcastle, NSW 2308, Australia

Leonie Ashman - *Discipline of Medical Biochemistry, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia*

## خلاصه مقاله:

**Objective(s):** Mutant forms FMS-like tyrosine kinase-<sup>3</sup> (FLT<sup>3</sup>), are reported in 25% of childhood acute lymphoid leukemia (ALL) and 30% of acute myeloid leukemia (AML) patients. In this study, drug response, growth promoting, and protein trafficking of FLT<sup>3</sup> wild-type was compared with two active mutants (Internal Tandem Duplication (ITD)) and D835Y. **Materials and Methods:** FLT<sup>3</sup> was expressed on factor-dependent cells (FDC-P1) using retroviral transduction. The inhibitory effects of CEP701, imatinib, dasatinib, PKC412 and sunitinib were studied on cell proliferation and FLT<sup>3</sup> tyrosine phosphorylation. Total expression and proportion of intracellular and surface FLT<sup>3</sup> was also determined. **Results:** FDC-P1 cells became factor-independent after expression of human FLT<sup>3</sup> mutants (ITD and D835Y). FDC-P1 cells expressing FLT<sup>3</sup>-ITD grow 3 to 4 times faster than those expressing FLT<sup>3</sup>-D835Y. FD-FLT<sup>3</sup>-ITD cells were three times more resistant to sunitinib than the FD-FLT<sup>3</sup>-WT cells. The Geo means for surface FLT<sup>3</sup> expression in FD-FLT<sup>3</sup>-ITD and -D835Y were 65 and 70% less than the FD-FLT<sup>3</sup>-WT cells. About 40% of expressed FLT<sup>3</sup> was detected as intracellular in FD-FLT<sup>3</sup>-D835Y cell compared to 4 and 4.5% in FD-FLT<sup>3</sup>-WT and -ITD cells. **Conclusion:** Retention of D835Y FLT<sup>3</sup> mutant protein may cause altered signaling, endoplasmic reticulum stress and activation of apoptotic signaling pathways leading to lower proliferation rate in FD-FLT<sup>3</sup>-D835Y than the FLT<sup>3</sup>-WT and ITD mutant., these may also contribute, along with the preferential affinity, to the increased sensitivity of D835Y of CEP701 and PKC412. Studying these genetic variations can help determining the prognosis and designing a therapeutic plan for the patients with FLT<sup>3</sup> mutations.

## کلمات کلیدی:

Activating mutation, Drug response, FLT<sup>3</sup>, Protein trafficking

## لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/1297747>



